$ETON 8-K SEC Filings

Filed On	Filing
14 Oct 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
28 Sep 2026	8-K: Other Events Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States
13 Aug 2026	8-K: Results of Operations and Financial Condition
05 Aug 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
04 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation
29 Jul 2026	8-K: Other Events
09 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
19 May 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
14 May 2026	8-K: Results of Operations and Financial Condition
01 May 2026	8-K: Other Events
27 Apr 2026	8-K: Other Events
16 Apr 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
15 Apr 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
19 Mar 2026	8-K: Results of Operations and Financial Condition
02 Mar 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
25 Feb 2026	8-K: Other Events
02 Feb 2026	8-K: Other Events
04 Dec 2025	8-K: Regulation FD Disclosure
06 Nov 2025	8-K: Results of Operations and Financial Condition
07 Aug 2025	8-K: Results of Operations and Financial Condition

Comments